Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

Not all health care professionals receive the same type of formal education. That may help explain the results of a new study ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ...

An expert discusses how underutilization of combination lipid-lowering therapies stems from overly complex guidelines, primary care providers managing multiple chronic diseases simultaneously, cost ...

"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...

Camrelizumab plus famitinib significantly improved PFS and OS compared to platinum-based chemotherapy in recurrent/metastatic cervical cancer. The trial reported a median PFS of 11.1 months for the ...

Discover Delcath’s innovative liver-targeted chemotherapy system and latest clinical data driving potential market expansion.

VCN-01 plus standard chemotherapy and Abraxane proved safe and effective for patients with metastatic pancreatic cancer.

The study results reflect the effect of surgery with lymph node dissection alone in patients with high-grade invasive bladder cancer.